A Phase 3 interventional study of ELX/TEZ/IVA and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 21 sites in 5 countries. Open to participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-10-22.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing elexacaftor in Cystic Fibrosis — 2 open to participants now, 5 under way, 2 of them phase 3. elexacaftor · Cystic Fibrosis.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, this one is the 17th largest by enrollment, is one of 2 that started in 2018, is one of 19 in phase 3, and was the 3rd registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 23 studies testing elexacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
elexacaftor: first FDA approval 2019 (TRIKAFTA (COPACKAGED)), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2018.
This study's enrollment of 71 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 120 across the 23 interventional studies. Of the 18 that completed or were terminated, 17 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 23 have an industry lead sponsor. The 4 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 59th largest by enrollment of the 116 interventional ones that give a count, is one of 13 that started in 2018, is one of 62 in phase 3, and was the 82nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
2 of the studies testing elexacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies testing elexacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the pharmacokinetics (PK), safety, tolerability, efficacy, and pharmacodynamic effect of VX-445, tezacaftor (TEZ), and ivacaftor (IVA) when dosed in triple combination (TC) in Cystic Fibrosis (CF) subjects 6 through 11 years of age with F/F and F/MF genotypes.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in Part A received ELX 100 milligrams (mg) once daily (qd)/TEZ 50 mg qd/IVA 75 mg every 12 hours (q12h) in the treatment period for 15 days.
Drug: ELX/TEZ/IVA · Drug: IVA
Participants in Part B weighing less than (\<) 30 kilograms (kg) at Day 1 received ELX 100 mg qd/TEZ 50 mg qd/IVA 75 mg q12h and participants weighing greater than equals to (\>=) 30 kg at Day 1 received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 24 weeks.
Drug: ELX/TEZ/IVA · Drug: IVA
Drug pages: Elexacaftor · Tezacaftor · Ivacaftor
Fixed-dose combination tablet orally once daily in the morning.
Also known as: VX-445/VX-661/VX-770, elexacaftor/tezacaftor/ivacaftor
IVA tablet orally once daily in the evening.
Also known as: VX-770, ivacaftor
Part A: Maximum Observed Plasma Concentration (Cmax) of ELX, TEZ, and IVA
Time frame: Part A: Day 15
Part A: Observed Pre-dose Plasma Concentration (Ctrough) of ELX, TEZ, and IVA
Time frame: Part A: Day 15
Part A: Area Under the Concentration Versus Time Curve From 0 to 24 Hours (AUC0-24h) of ELX, TEZ, and IVA
Time frame: Part A: Day 15
Part B: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: Part B: Day 1 Through Safety Follow-up Visit (up to Week 28)
Part A: Cmax of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame: Part A: Day 15
Part A: Ctrough of ELX Metabolite (M23-ELX), TEZ Metabolite (M1-TEZ), and IVA Metabolite (M1-IVA)
Time frame: Part A: Day 15
Part A: AUC0-24h of ELX Metabolite (M23-ELX) and TEZ Metabolite (M1-TEZ)
Time frame: Part A: Day 15
Part A: Area Under the Concentration Versus Time Curve From 0 to 6 Hours (AUC0-6h) of IVA Metabolite (M1-IVA)
The AUC data was analyzed for up to 6 hours for IVA metabolite (M1-IVA). Therefore, AUC0-6h is reported for M1-IVA metabolite.
Time frame: Part A: Day 15
Part A: Safety and Tolerability as Assessed by Number of Participants With TEAEs and SAEs
Time frame: Part A: Day 1 Through Safety Follow-up Visit (up to Day 43)
Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
Time frame: Part B: From Baseline Through Week 24
Part B: Absolute Change in Sweat Chloride (SwCl)
Sweat samples were collected using an approved collection device.
Time frame: Part B: From Baseline Through Week 24
Part B: Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
Time frame: Part B: From Baseline Through Week 24
Part B: Absolute Change in Body Mass Index (BMI)
BMI was defined as weight in kg divided by squared height in meters (m\^2).
Time frame: Part B: From Baseline at Week 24
Part B: Absolute Change in BMI For-Age Z-Score
BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
Time frame: Part B: From Baseline at Week 24
Part B: Absolute Change in Weight
Time frame: Part B: From Baseline at Week 24
Part B: Absolute Change in Weight-for-age Z-Score
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
Time frame: Part B: From Baseline at Week 24
Part B: Absolute Change in Height
Time frame: Part B: From Baseline at Week 24
Part B: Absolute Change in Height-for-Age Z-Score
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
Time frame: Part B: From Baseline at Week 24
Part B: Drug Acceptability Assessment Using Modified Facial Hedonic Scale
The study drug acceptability (participant reaction) was assessed by a visual analog scale that incorporates a 5 point facial hedonic scale (Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much). Number of participants with the indicated categorical response in the drug acceptability assessment were reported.
Time frame: Part B: At Week 24
Part B: Number of Pulmonary Exacerbations Events
Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria. The total number of pulmonary exacerbations events across all participants were reported.
Time frame: Part B: From Baseline Through Week 24
Part B: Number of CF Related Hospitalizations
The total number of CF related hospitalization events across all participants were reported.
Time frame: Part B: From Baseline Through Week 24
Part B: Ctrough of ELX, ELX Metabolite (M23-ELX), TEZ, TEZ Metabolite (M1-TEZ), IVA and IVA Metabolite (M1-IVA)
Time frame: Part B: At Week 4
Part B: Absolute Change in Lung Clearance Index 2.5 (LCI2.5)
LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
Time frame: Part B: From Baseline Through Week 24
The study was conducted in 2 parts, Part A and Part B. All results were planned to be analyzed and reported separately for Part A and Part B of the study.
| Milestone | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Started | 16 | 0 |
| Completed | 16 | 0 |
| Not completed | 0 | 0 |
| Milestone | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Started | 0 | 66 |
| Completed | 0 | 64 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal of consent (not due to ae) | 0 | 1 |
| microgram per milliliter (mcg/mL) | Part A: ELX/TEZ/IVA |
|---|---|
| ELX | 6.13 ± 1.52 |
| TEZ | 6.93 ± 1.96 |
| IVA | 1.01 ± 0.281 |
| mcg/mL | Part A: ELX/TEZ/IVA |
|---|---|
| ELX | 2.86 ± 1.37 |
| TEZ | 1.06 ± 0.366 |
| IVA | 0.297 ± 0.173 |
| hour*microgram per milliliter (h*mcg/mL) | Part A: ELX/TEZ/IVA |
|---|---|
| ELX | 107 ± 28.7 |
| TEZ | 58.4 ± 13.5 |
| IVA | 8.12 ± 2.93 |
| participants | Part B: ELX/TEZ/IVA |
|---|---|
| Participants With TEAEs | 65 |
| Participants With SAEs | 1 |
| mcg/mL | Part A: ELX/TEZ/IVA |
|---|---|
| M23-ELX | 1.60 ± 0.657 |
| M1-TEZ | 6.26 ± 1.54 |
| M1-IVA | 2.36 ± 0.694 |
| mcg/mL | Part A: ELX/TEZ/IVA |
|---|---|
| M23-ELX | 1.30 ± 0.585 |
| M1-TEZ | 4.64 ± 1.36 |
| M1-IVA | 0.890 ± 0.460 |
| h*mcg/mL | Part A: ELX/TEZ/IVA |
|---|---|
| M23-ELX | 35.6 ± 13.2 |
| M1-TEZ | 133 ± 30.4 |
The AUC data was analyzed for up to 6 hours for IVA metabolite (M1-IVA). Therefore, AUC0-6h is reported for M1-IVA metabolite.
| h*mcg/mL | Part A: ELX/TEZ/IVA |
|---|---|
| Part A: Area Under the Concentration Versus Time Curve From 0 to 6 Hours (AUC0-6h) of IVA Metabolite (M1-IVA) | 9.41 ± 3.06 |
| participants | Part A: ELX/TEZ/IVA |
|---|---|
| Participants With TEAEs | 12 |
| Participants With SAEs | 0 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
| percentage points | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) | 10.2 (7.9 to 12.6) |
Sweat samples were collected using an approved collection device.
| millimole per liter (mmol/L) | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Sweat Chloride (SwCl) | -60.9 (-63.7 to -58.2) |
The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.
| units on a scale | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score | 7.0 (4.7 to 9.2) |
BMI was defined as weight in kg divided by squared height in meters (m\^2).
| kg/m^2 | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Body Mass Index (BMI) | 1.02 (0.76 to 1.28) |
BMI was defined as weight in kg divided by squared height in meters (m\^2). The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
| z-score | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in BMI For-Age Z-Score | 0.37 (0.26 to 0.48) |
| kg | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Weight | 3.0 (2.5 to 3.5) |
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
| z-score | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Weight-for-age Z-Score | 0.25 (0.16 to 0.33) |
| centimeters (cm) | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Height | 2.3 (1.9 to 2.7) |
The z-score is a statistical measure to describe whether a value was above or below the standard. A z-score of 0 is equal to the standard. Lower numbers indicate values lower than the standard and higher numbers indicate values higher than the standard.
| z-score | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Height-for-Age Z-Score | -0.05 (-0.12 to 0.01) |
The study drug acceptability (participant reaction) was assessed by a visual analog scale that incorporates a 5 point facial hedonic scale (Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much). Number of participants with the indicated categorical response in the drug acceptability assessment were reported.
| participants | Part B: ELX/TEZ/IVA |
|---|---|
| Liked it Very Much | 16 |
| Liked it a Little | 6 |
| Not sure | 10 |
| Disliked it a Little | 1 |
| Disliked it Very Much | 0 |
Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria. The total number of pulmonary exacerbations events across all participants were reported.
| pulmonary exacerbations events | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Number of Pulmonary Exacerbations Events | 4 |
The total number of CF related hospitalization events across all participants were reported.
| hospitalizations | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Number of CF Related Hospitalizations | 0 |
| mcg/mL | Part B: ELX/TEZ/IVA |
|---|---|
| ELX: Week 4 (<30 kg) | 2.71 ± 1.77 |
| ELX: Week 4 (>=30 kg) | 5.69 ± 3.00 |
| M23-ELX: Week 4 (<30 kg) | 1.59 ± 1.24 |
| M23-ELX: Week 4 (>=30 kg) | 4.41 ± 2.97 |
| TEZ: Week 4 (<30 kg) | 1.43 ± 1.19 |
| TEZ: Week 4 (>=30 kg) | 2.37 ± 1.07 |
| M1-TEZ: Week 4 (<30 kg) | 5.57 ± 1.78 |
| M1-TEZ: Week 4 (>=30 kg) | 8.12 ± 1.88 |
| IVA: Week 4 (<30 kg) | 0.455 ± 0.681 |
| IVA: Week 4 (>=30 kg) | 0.851 ± 0.489 |
| M1-IVA: Week 4 (<30 kg) | 1.00 ± 0.630 |
| M1-IVA: Week 4 (>=30 kg) | 2.18 ± 1.04 |
LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.
| lung clearance index | Part B: ELX/TEZ/IVA |
|---|---|
| Part B: Absolute Change in Lung Clearance Index 2.5 (LCI2.5) | -1.71 (-2.11 to -1.30) |
Collected over Day 1 Through Safety Follow-up Visit (up to Day 43 for Part A, up to Week 28 for Part B). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: ELX/TEZ/IVA | 0/16 (0%) | 0/16 (0%) | 12/16 (75%) |
| Part B: ELX/TEZ/IVA | 0/66 (0%) | 1/66 (1.5%) | 62/66 (93.9%) |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| Metapneumovirus infectionInfections and infestations | 0/16 | 1/66 |
| PneumoniaInfections and infestations | 0/16 | 1/66 |
| Rhinovirus infectionInfections and infestations | 0/16 | 1/66 |
| Event | Part A: ELX/TEZ/IVA | Part B: ELX/TEZ/IVA |
|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 5/16 | 28/66 |
| HeadacheNervous system disorders | 0/16 | 16/66 |
| PyrexiaGeneral disorders | 1/16 | 14/66 |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 3/16 | 3/66 |
| RashSkin and subcutaneous tissue disorders | 3/16 | 8/66 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/16 | 12/66 |
| Upper respiratory tract infectionInfections and infestations | 0/16 | 11/66 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 2/16 | 10/66 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 2/16 | 5/66 |
| Abdominal painGastrointestinal disorders | 1/16 | 8/66 |
The analysis population included all enrolled participants who carry the intended CFTR allele mutation and received at least 1 dose of study drug in the respective part of the study.
| Age, Categorical(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — <=18 years | 16 |
| Part A (15 Days) — Between 18 and 65 years | 0 |
| Part A (15 Days) — >=65 years | 0 |
| Part B (24 Weeks) — <=18 years | 66 |
| Part B (24 Weeks) — Between 18 and 65 years | 0 |
| Part B (24 Weeks) — >=65 years | 0 |
| Sex: Female, Male(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — Female | 11 |
| Part A (15 Days) — Male | 5 |
| Part B (24 Weeks) — Female | 39 |
| Part B (24 Weeks) — Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — Hispanic or Latino | 0 |
| Part A (15 Days) — Not Hispanic or Latino | 16 |
| Part A (15 Days) — Unknown or Not Reported | 0 |
| Part B (24 Weeks) — Hispanic or Latino | 0 |
| Part B (24 Weeks) — Not Hispanic or Latino | 58 |
| Part B (24 Weeks) — Unknown or Not Reported | 8 |
| Race (NIH/OMB)(Participants) | ELX/TEZ/IVA |
|---|---|
| Part A (15 Days) — American Indian or Alaska Native | 0 |
| Part A (15 Days) — Asian | 0 |
| Part A (15 Days) — Native Hawaiian or Other Pacific Islander | 0 |
| Part A (15 Days) — Black or African American | 0 |
| Part A (15 Days) — White | 16 |
| Part A (15 Days) — More than one race | 0 |
| Part A (15 Days) — Unknown or Not Reported | 0 |
| Part B (24 Weeks) — American Indian or Alaska Native | 0 |
| Part B (24 Weeks) — Asian | 0 |
| Part B (24 Weeks) — Native Hawaiian or Other Pacific Islander | 0 |
| Part B (24 Weeks) — Black or African American | 0 |
| Part B (24 Weeks) — White | 57 |
| Part B (24 Weeks) — More than one race | 1 |
| Part B (24 Weeks) — Unknown or Not Reported | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2018 to primary completion in Aug 2020, 22 months.
Results were first posted in Oct 2021, 1 year 2 months after primary completion.
Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 22 months is below that.
Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elexacaftor · Tezacaftor · Ivacaftor
Vertex Pharmaceuticals Incorporated →